US Drug Supply Chain Reshoring Sparks A New Microcap Theme; FRTU President Yoel Damas Addresses Growth, Capital, Automation, And Nasdaq Plans [GeoWire Weekly No. 249]

If you are a premium member make sure you sign in to see All the exclusive content In This Issue.

SIGN IN

This week’s Microcap Information Arbitrage Weekly Wrap-Up is ready — spotlighting the most important developments across our 1,500+ microcap coverage universe built since 2009, including high-impact earnings reports, information arbitrage discoveries, contract announcements, and model portfolio updates. We also highlight insights from our investor and CEO interviews (Skull Sessions).

See all emails sent during the week here.

As usual, we highlight the stocks we want to watch most in our big movers and losers list of the week, included at the end of this post.

This week was pretty quiet ahead of the increase in small-cap earnings that’s about to arrive.

Feature Highlight From Our Microcap Coverage Universe

A US policy shock, a long-running national-security concern about drug supply, finally crystallized into tariffs, is pushing pharmaceutical manufacturing back onto American soil. The result is a domestic capital-expenditure wave estimated at roughly $370–480 billion of announced commitments through 2030. The durable money in this theme does not sit with the drugmakers, for whom reshoring is a cost, but with the “picks and shovels”: the engineering, process-equipment, and consumables suppliers who design, build, and outfit the new plants.

The vulnerability itself is old. The US has long depended on China and India for the active pharmaceutical ingredients (APIs), the molecules that actually do the work inside a drug, and for much of its finished-drug supply. COVID turned that quiet dependence into an obvious strategic risk: a foreign supply-chain disruption can leave the country short of medicines it cannot quickly make itself. What changed in 2025–26 is that the concern was finally given teeth, through three distinct policy actions:

• Tariffs on branded drugs (April 2026): The US finalized Section 232 tariffs on patented, branded medicines, deliberately tiered to reward domestic production; a company that commits to building in the US can face a 0% rate, while one that does not can be tariffed as steeply as 100%.
• Generic-drug tariff plan (announced July 2026): The administration then unveiled a phased plan to tariff low-cost generics, largely sourced from India, escalating toward rates as high as 200% over the next few years, with a grace period to reshore. Unlike the two measures above, this one is a proposal rather than enacted policy, but it signals the same intent to the cheaper end of the market.
• The BIOSECURE Act (law, December 2025): This steers drugmakers away from using Chinese contract manufacturers for biologic medicines, closing off a major offshore route for the industry’s fastest-growing drug class.

Together, the message to the industry is unambiguous: manufacture here, or pay to sell here. Identifying the ultimate winners of this trend is still a work in progress, but two microcaps have already surfaced as potential beneficiaries: Sign in or join today to reveal stocks.

By the way, if you haven’t noticed yet, InfoArbMonitor (infoarb.io) v2.6.0 now includes an Earnings Calendar that was built specifically for investors. Use it to:

• See what companies are reporting each day
• Build your watchlist ahead of earnings
• Build advanced filters based on the keywords that matter most to you
• Start to use the advanced earnings calendar as your go to place to set earnings conference call alerts
• Make sure you don’t miss the companies you’re following

So far, it looks like 250+ smaller-cap companies are scheduled to report earnings this week, including Champions Oncology, Inc. (NASDAQ:CSBR), Orion Group Holdings, Inc. (NYSE:ORN), and Spok Holdings, Inc. (NASDAQ:SPOK).

Stocks discussed at Geoinvesting last week: 

Feature Stock: A shift toward domestic pharmaceutical manufacturing could create an opportunity for companies like Sign in or join today to reveal stocks. We don’t think it’s a theme that many people are watching, yet.

Model Portfolio Updates: Two new stocks added to Select Coverage Universe Model Portfolio

Earnings: FSI REOP RELL BURCA

Updates: NNBR BOF KLNG FACO

InfoArb Tear Sheets: PKE PHM RELL JAKK BWMX NDLS

Skull Sessions: Management briefing with FRTU President Yoel Damas addressing questions from Geoinvesting subscribers regarding funding capacity, underwriting automation, its audit, and a potential uplisting.

---

***In case you missed last week’s Wrap-up, it’s available here***

Inside this Week’s Report: 

1. Model Portfolio Updates & Research Screen Updates
2. Earnings Reports Worth Monitoring
3. Business & Operational Developments
4. Latest InfoArb Tear Sheets
5. Skull Sessions
6. Coverage Universe Stats: Big Movers & Losers and New Highs & Lows

---

——

Sorry, the full post is only available for paying subscribers. If you are already a paying subscriber, please make sure you are logged in. To become a paying subscriber please click on the link below

(We also offer a new very popular monthly subscription option).

gain Exposure to our expanded coverage on Our 1500+ Microcap Universe, Subscribe below.

SIGN IN

200+ multibaggers and counting

---

---

GeoInvesting is a premier research platform for microcap investors, dedicated to uncovering high-potential stock ideas in undervalued companies across various sectors. With over 30 years of investing experience, GeoInvesting has covered more than 1,500 equities, providing often actionable proprietary research. The platform has been instrumental in identifying 200+ multibagger stocks, and offers investors exclusive access to over 600 management interview clips, allowing for deeper due diligence and understanding of the microcap stocks, many of which make it to market-beating premium Model Portfolios. Join the GeoInvesting community for the best stock research and microcap insights to help you stay ahead in the market. To learn more about our Premium Services, go here.. (https://geoinvesting.com/premium-research/)

The post US Drug Supply Chain Reshoring Sparks A New Microcap Theme; FRTU President Yoel Damas Addresses Growth, Capital, Automation, And Nasdaq Plans [GeoWire Weekly No. 249] appeared first on GeoInvesting.

Source: https://geoinvesting.com/us-drug-supply-chain-reshoring-sparks-a-new-microcap-theme-frtu-president-yoel-damas-addresses-growth-capital-automation-and-nasdaq-plans-geowire-weekly-no-249/